Application of myeloperoxidase and lipoprotein associated phospholipase A2 in the diagnosis of cardiovascular diseases

doi:10.3877/cma.j.issn.2095-5820.2019.04.011

Abstract

Abstract:

Objective

To compare plasma levels of myeloperoxidase (MPO) and lipoprotein-associated phospholipase A₂ (Lp-PLA₂) between patients with cardiovascular diseases and healthy controls, and to evaluate the role of MPO and Lp-PLA₂ in the diagnosis of cardiovascular diseases.

Methods

Seventy-two patients with cardiovascular diseases confirmed by coronary angiography and radionuclide labeling were selected as the disease group, and 68 healthy people as the control group. The levels of plasma MPO and Lp-PLA₂ of the two groups were measured by enzyme-linked immunosorbent assay (ELISA). The differences between the two groups were compared, and the results were statistical analyzed.

Results

By comparing the levels of MPO and Lp-PLA₂ between the cardiovascular disease and the healthy control groups, the results showed that there was significant differences between the two gooups. The levels of MPO and Lp-PLA₂ in the disease group were significantly higher than those in the healthy control group. ROC curve suggested that the diagnostic accuracy of MPO and Lp-PLA₂ for cardiovascular diseases was higher than 50% and higher than 90%, respectively.

Conclusion

The levels of MPO and Lp-PLA₂ in the plasma of patients with cardiovascular diseases significantly increases, suggesting their diagnostic value.

Key words: Myeloperoxidase, Lipoprotein-associated phospholipase A₂, Coronary heart disease, Enzyme-linked immunosorbent assay

Ying Wang, Xuejun Chen. Application of myeloperoxidase and lipoprotein associated phospholipase A₂ in the diagnosis of cardiovascular diseases[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(04): 234-237.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2019.04.011

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2019/V07/I04/234

Figures/Tables 5

References 18

1	Liu CG, Chen LN, Yang YZ, et al. Myeloperoxidase and high-sensitivity C-reactive protein for predicting major adverse cardiovascular events in patients with coronary heart disease[J]. Int J Clin Med, 2015,6:262-270.
2	Uydu HA, Bostan M, Yilmaz A, et al. Comparison of inflammatory biomarkersfor detection of coronary stenosis in patients with stable coronary artery disease[J]. Eur Rev Med Pharmacol Sci, 2013,17(1):112-118.
3	Khan AA, Alsahli MA, Rahmani AH. Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives[J]. Med Sci (Basel), 2018,6(2).pii: E33.
4	Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction[J]. J Geriatr Cardiol, 2017,14(2):135-150.
5	胡大一，杨铁生，刘梅颜，等. 心脏分子标志物临床应用[M]. 北京：人民军医出版社, 2009:143-149.
6	许俊堂，丛玉隆. 抗栓与溶栓药物的血液学检测[J]. 中华检验医学杂志, 2001,24(1):53-55.
7	Roman RM, Camargo PV, Borges FK, et al. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients[J]. Coron Artery Dis, 2010,21(3):129-136.
8	Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction[J]. Biomed Rep, 2015,3(6):743-748.
9	Quidim AV, Bruno TC, Lacerda Leocádio PC, et al. Myeloperoxidase activity and acute coronary syndrome survival: long-term evaluation in the ERICO study[J]. Biomark Med, 2018,12(11):1219-1229.
10	Goiffon RJ, Martinez SC, Piwnica-Worms D. A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma[J]. Nat Commun, 2015,10(6):6271.
11	Kocak S, Ertekin B, Girisgin AS, et al. Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke[J]. Turk J Emerg Med, 2017,17(2):56-60.
12	Wright CB, Moon Y, Paik MC, et al. Inflammatory biomarkers of vascular risk as correlates of leukoaraiosis[J]. Stroke. 2009,40(11):3466-3471.
13	Yang L, Liu Y, Wang SF, et al. Association between Lp-PLA2 and coronary heart disease in Chinese patients[J]. J Int Med Res, 2017,45(1):159-169.
14	Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2[J]. J Lipid Res, 2012,53(9):1767-1782.
15	Yang YP, Xue T, Zhu JH, et al. Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction[J]. Clin Neurol Neurosurq, 2017,160:40-45.
16	Li JW, Wang H, Tian JP, et al. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome[J]. Medicine (Baltimore), 2018,97(28):e11517.
17	Omran MM, Zahran FM, Kadry M, et al. Role of myeloperoxidase in early diagnosis of acute myocardial infarction in patients admitted with chest pain[J]. J Immunoassay Immunochem, 2018,39(3):337-347.
18	Güngör ZB, Tüten A, Ekmekçi H, et al. Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia[J]. J Matern Fatal Med, 2018,31(23):3119-3127.

组别	例数(例)	年龄(岁)	性别(男/女)
患病组	72	62.35±9.62	38/34
健康对照组	68	60.22±8.64	33/35
P值	?	0.172	0.618

组别	例数(例)	年龄(岁)	性别(男/女)
患病组	72	62.35±9.62	38/34
健康对照组	68	60.22±8.64	33/35
P值	?	0.172	0.618

组别	例数	MPO(ng/mL)	Lp-PLA₂(ng/mL)	TC(mmol/L)	LDL-C(mmol/L)	HDL-C(mmol/L)	TG(mmol/L)
患病组	72	123.78±32.03	230.28±45.42	4.82±0.93	3.53±0.81	1.14±0.26	1.76±0.76
健康对照组	68	74.97±29.74	147.60±37.36	4.67±0.65	3.34±0.47	1.11±0.13	1.70±0.43
t值	?	9.711	11.726	1.373	1.136	1.578	0.862
P值	?	<0.05	<0.05	0.172	0.258	0.117	0.390

组别	例数	MPO(ng/mL)	Lp-PLA₂(ng/mL)	TC(mmol/L)	LDL-C(mmol/L)	HDL-C(mmol/L)	TG(mmol/L)
患病组	72	123.78±32.03	230.28±45.42	4.82±0.93	3.53±0.81	1.14±0.26	1.76±0.76
健康对照组	68	74.97±29.74	147.60±37.36	4.67±0.65	3.34±0.47	1.11±0.13	1.70±0.43
t值	?	9.711	11.726	1.373	1.136	1.578	0.862
P值	?	<0.05	<0.05	0.172	0.258	0.117	0.390

?	MPO	Lp-PLA₂	TC	LDL-C	HDL-C	TG	年龄
MPO	1	0.782	0.053	0.026	0.044	0.021	0.007
MPO	?	<0.05	0.535	0.757	0.609	0.807	0.933
Lp-PLA₂	0.782	1	-0.009	0.027	0.034	-0.069	0.059
Lp-PLA₂	<0.05	?	0.915	0.748	0.692	0.418	0.491

Please choose a citation manager

Content to export

Application of myeloperoxidase and lipoprotein associated phospholipase A₂ in the diagnosis of cardiovascular diseases

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 5

References 18

Related Articles 15

Recommended Articles

Metrics

Comments

?	敏感度	特异性	总符合率	假阴性率	假阳性率	阳性预测值	阴性预测值
MPO	84.7%	76.5%	80.7%	15.3%	23.5%	79.2%	82.5%
Lp-PLA₂	86.1%	83.8%	85.0%	13.9%	16.2%	84.9%	85.1%

[1]	Daorina Bao, Siying Liang, Tiangang Zhu. Clinical value of contrast echocardiography in diagnosing complications and assessing cardiac function in patients with coronary heart disease [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2021, 18(05): 482-486.
[2]	Yang Shen, Haibo Yu, Qiangying Zeng. Predictive value of peripheral blood levels of soluble Fas protein, soluble Fas protein ligand and myeloperoxidase on poor prognosis in children with severe pneumonia [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(04): 268-274.
[3]	Tuerdehan Ayibieke·, Lunjian Chen, Kalifu Baheti·, Xiong Chen, Yuan Meng. Value of serum immune antigens in the diagnosis of hydatid disease: a Meta-analysis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(03): 300-304.
[4]	Hui Pang, Hao Yang, Qiang Fu, Peng Guo, Zhenkun Zong. Application of CHA₂DS₂-VASc score in stroke risk prediction in patients with hypertension and coronary heart disease [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2022, 08(02): 69-75.
[5]	Jie Chen, Feng Zhou, Jinbo Liu, Hongyu Wang. Drug therapy pattern and population heterogeneity of patients with coronary heart disease based on cluster analysis [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(10): 1012-1018.
[6]	Qi Cai, Yonghong Yong, Hua He, Tongsheng She, Hui Yu. Evaluation of left ventricular function in patients with coronary heart disease by three-dimensional speckle tracking imaging combined with serum homocysteine [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(05): 425-430.
[7]	Xian Chen, Junhong Kong, Chenxi Sha, Chuqiao Gong. Exploration of therapeutic mechanism of Maitong Yin for coronary heart disease based on network pharmacology [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(11): 882-889.
[8]	Tong Shen, Cheng Shen, Yanyan Zhang, Xinzhuo Yan, Lijun Gan. One case of death in a patient with coronary heart disease complicated with rheumatoid arthritis after PCI [J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(04): 241-244.
[9]	Yicheng Guo, Zhipeng Xie, Wanli Liu, Yang Zhao, Yansheng Che, Min Zhao. Characteristic analysis of precordial referred pain caused by osteoporotic vertebral compression fracture in the 12th thoracic vertebrae misdiagnosed as coronary heart disease [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(02): 136-139.
[10]	Kuanping Ye, Hua Li, Xiaowen Ma, Xiaoyan Liu, Fengling Chen. Relationship between serum uric acid level and Framingham 10-year risk of coronary heart disease in patients with type 2 diabetes mellitus [J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(03): 145-151.
[11]	Jianzhi Lyu, Jinghe Cao, Huan Liu, Xinzhe Wang, Susu Shi, Haizhou Zhu. Clinical significance of IGFBP2 and ERK1/2 expression in clear cell renal cell carcinoma [J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(01): 42-47.
[12]	Dongmei Xu, Li Sun, Lan Wei, Shiyin Zhai, Xinyue Zhang. Study on the status and influencing factors of ruminant meditation in patients with secondary percutaneous coronary intervention [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(04): 230-234.
[13]	Shaohua Guo, Shijia Geng, Shenda Hong, Guanyu Mu, Yizhi Zhang, Lei Yang, Tong Liu, Kangyin Chen. Use of an artificial intelligence-enabled electrocardiogram for screening people without coronary heart disease [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(01): 18-23.
[14]	Jingran Cao, Fuqiang Dong, Lijian Zhang, Changle Liu, Yukun Zhang, Kangyin Chen. Screening of nutritional risk, sarcopenia and frailty in older inpatients with coronary heart disease [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2024, 11(02): 5-9.
[15]	Yongna Feng, Tingyu Tang, Fangchao Lyu, Lan Chen. Correlation between small airway function and elderly coronary heart disease [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2022, 09(03): 17-20.

模态框（Modal）标题

Please choose a citation manager

Content to export